ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 1
Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC
This episode explores expert insights on the clinical use of osimertinib in the frontline setting for EGFR-mutated NSCLC, the impact of combining osimertinib with platinum-based chemotherapy on progression-free survival (PFS), and the significance of extending PFS by nearly 9 months in patients with advanced NSCLC who are not candidates for curative treatment.
Video content above is prompted by the following:
- What has been your clinical experience with osimertinib in the frontline setting for EGFR-mutated NSCLC?
- Please assess the impact of a 38% improvement in PFS with the combination of osimertinib and platinum-based chemotherapy vs osimertinib monotherapy in patients with advanced EGFR-mutated NSCLC.
- From the perspective of a community oncologist, please share your insights on the meaningful benefit of extending PFS an additional 8.8-9.5 months among untreated patients with advanced NSCLC, not amenable to curative resection or radiotherapy.
Related Content:
